Skip to main content
OpenTrials
Completed

NCT Number: NCT05098691

Early Onset Preeclampsia and Nectin-4

Early-onset Preeclampsia (PE) is a pregnancy disorder which may present with adverse pregnancy outcomes. Nectin-4 is an adhesion molecule mainly expressed in placenta. This study aimed to evaluate the relationship between early onset Preeclampsia and serum Nectin 4 levels.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Hatice Akkaya

Istanbul, 34010, Turkey (Türkiye)

About this study

Preeclampsia is assumed as a two-stage disorder arising from defective trophoblast invasion and failure of spiral artery remodeling as the main step responsible for the pathogenesis. PE is classified according to the disease onset time as early-onset PE before 34 weeks and late-onset PE after 34 weeks. Late-onset PE is more commonly seen and accepted as a mild maternal reaction to pregnancy. In early-onset PE, unlike the late-onset, due to the improper placental invasion, the diffuse placental ischemia and the resulting oxidative stress begin at early gestation. Thus, the early-onset PE may result in severe disease leading to perinatal and maternal morbidity and mortality.

The nectins are calcium-independent immunoglobulin-like celladhesion molecules and have a pivotal role at cellular junctions, as well as physiological regulations(8). Placenta expressesfor types of nectins; nectin-1, nectin-2, nectin-3, and nectin-4. They are localized at tight junctions and gap junctions of syncitiotrophoblasts(9). Nectin-4 is a relatively novel member of nectin family which has been detected only in placenta and airway epithelium in healthy subjects.

Despite, there has been no study published yet to reveal the soluble nectin-4 levels in preeclampsia as well as in early onset disease. In this study, we aimed to investigate the serum nectin-4 levels in early-onset preeclampsia in comparison of the healthy pregnancies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • spontaneous,
  • singleton pregnancies
  • above the 24 weeks of gestations
  • positive fetal cardiac activity

Exclusion criteria

  • multiple gestations,
  • chronic hypertension
  • hypothyroidism
  • known malignancy,- diabetes mellitus,
  • presence of fetal or maternal infection,
  • clinical signs of chorioamnionitis (maternal fever, vaginal discharge, fetal tachycardia),
  • hepatic or renal failure
  • Placenta previa or pregnancies accompanied congenital fetal abnormalities or aneuploidies

Treatment and study plan

serum marker levels

Diagnostic Test

two groups comparisons

Primary outcomes

  1. serum nectin-4 levels

    Time frame: 1 hour

    ng/ml

Secondary outcomes

  1. BMI (body mass index)

    Time frame: 5 minute

    kg/m2

  2. Tansion Arterial

    Time frame: 5 minute

    mm Hg

Sponsors and collaborators

Lead sponsor

Hatice Akkaya

Other Gov

Registry information

Official study title

Serum Nectin-4 Levels in Patients With Early Onset Preeclampsia

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 28, 2021
Registry last updated
Oct 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.